Stockscreener 앱 받기
826.28
0.95%
7.78
시간 외 거래:
826.28
Argen X Se Adr 주식(ARGX)의 최신 뉴스
Vyvgart Fuels Strong Growth for Argenx and Supports Developing Pipeline - Morningstar
argenx SE stock price target raised to $1,146 from $800 at TD Cowen - Investing.com Philippines
argenx ADR earnings beat by $0.74, revenue topped estimates - Investing.com Canada
Argenx rises after Q3 earnings beat on strong sales growth By Investing.com - Investing.com South Africa
Argenx rises after Q3 earnings beat on strong sales growth - Investing.com India
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update - Sahm
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients - GlobeNewswire Inc.
Baron Health Care Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025 - Sahm
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
Argx stock hits all-time high at 821.97 USD By Investing.com - Investing.com Philippines
Argx stock hits all-time high at 821.97 USD - Investing.com India
TD Cowen Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
argenx stock price target maintained at $800 by TD Cowen on strong Vyvgart uptake - Investing.com
Argenx Se (ARGX) Gets a Buy from Evercore ISI - The Globe and Mail
How Do Investors Really Feel About argenx SE? - Sahm
RBC Capital Remains a Buy on Argenx Se (ARGX) - The Globe and Mail
Argenx SE Sponsored ADR (ARGX) Stock Forecast & Price Targets: Today, Tomorrow, Next Week - Traders Union
Stocks Showing Improved Relative Strength: Zai Lab ADR - inkl
Argenx NV stock hits all-time high at 803.95 USD By Investing.com - Investing.com South Africa
Argenx NV stock hits all-time high at 803.95 USD - Investing.com
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes - 富途牛牛
Argenx SE Calls Extraordinary Shareholder Meeting for November 2025 - The Globe and Mail
Structure Therap ADR Earns Relative Strength Rating Upgrade - inkl
Goldman Sachs Sticks to Its Buy Rating for Argenx Se (ARGX) - The Globe and Mail
Argenx stock hits all-time high at 781.12 USD By Investing.com - Investing.com Australia
Argenx stock hits all-time high at 781.12 USD - Investing.com
Argenx Se (ARGX) Receives a Buy from RBC Capital - The Globe and Mail
Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today - Sahm
Barclays Sticks to Its Buy Rating for Lonza Group Ltd (LONN) - The Globe and Mail
Price Over Earnings Overview: argenx - Sahm
Leerink Partners Keeps Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Barclays Sticks to Their Hold Rating for Roche Holding AG (RHHVF) - The Globe and Mail
Argenx Se (ARGX) Receives a Rating Update from a Top Analyst - The Globe and Mail
Oppenheimer reaffirms Outperform rating on argenx stock after positive data - Investing.com
Truist Securities reiterates Buy rating on argenx stock with $918 target - Investing.com
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Truist Securities assumes coverage on argenx stock with Buy rating - Investing.com
Deutsche Bank downgrades Argenx to “hold” after 40% rally, €655 PT intact - Investing.com
14 Newly Overvalued Stocks for the Week - Morningstar
BofA Securities reaffirms Buy rating on argenx stock with $887 target - Investing.com
Argenx stock hits all-time high at 716.89 USD - Investing.com
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily
Piper Sandler raises argenx stock price target to $820 on Vyvgart success - Investing.com
European Stocks Slip Slightly In US Trading To Start The Week - Finimize
Argenx Tops Buy Point On Bullish Study, 850 Price Target - Investor's Business Daily
Argenx stock reaches all-time high at 696.94 USD - Investing.com
Argenx: study met primary endpoint - AInvest
Argenx Shares Rise 0.42% with $190M Volume Ranking 464th Amid Biotech Sector Surge - AInvest
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Earnings call transcript: Argenx Q2 2025 reports robust earnings beat - Investing.com
Argenx's Growth Fuels Strong Demand for Vyvgart; Pipeline Continues to Develop - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - GlobeNewswire Inc.
4.82%
0.44%
자본화:
|
볼륨(24시간):